RecruitingNCT06807099

WRAP North America

Prospective, Multicenter, Observational Study to Evaluate the Merit WRAPSODY® Cell Impermeable Endoprosthesis for Treatment of Stenosis or Occlusion Within the Dialysis Outflow Circuit (WRAP North America)


Sponsor

Merit Medical Systems, Inc.

Enrollment

250 participants

Start Date

Jul 31, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to investigate the safety and efficacy of the WRAPSODY CIE in a real-world North American population. Participants treated with the WRAPSODY CIE device in accordance with the device instructions for use will be followed in accordance with standard of care up to 3-years post-procedure.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Subject provides written informed consent for study participation.
  • Subject is male or female, with an age ≥ 18 years at date of enrollment.
  • Subject is willing to comply with site standard of care procedures and follow-up visit schedules over 36 months.
  • Subject is undergoing chronic hemodialysis with the hemodialysis access the intervention will be performed upon.
  • The dialysis access is considered mature and has been used to deliver hemodialysis treatments for at least one session.
  • Subject has stenosis or occlusion within the dialysis outflow circuit and is treated with WRAPSODY CIE in accordance with device instructions for use.

Exclusion Criteria9

  • Subject has a planned surgical revision of access site.
  • Subject has a known or suspected infection of the hemodialysis access site, systemic infection and/or septicemia.
  • Subject has an uncorrectable coagulation disorder.
  • Known hypersensitivity to nickel or titanium.
  • Subject's hemodialysis access is anticipated to be abandoned within 6 months.
  • Subject is scheduled for kidney transplant or peritoneal dialysis within the next 6 months post-procedure.
  • Full expansion of a PTA balloon cannot be achieved during predilatation.
  • Device would be placed in the Superior Vena Cava
  • Any inflow or outflow lesion that could jeopardize patency access long-term beyond the target treatment area.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEMerit WRAPSODY® Cell Impermeable Endoprosthesis (WRAPSODY CIE)

Target Lesion treated with WRAPSODY CIE


Locations(12)

Trinity Research Group

Dothan, Alabama, United States

Sarasota Memorial Research Institute

Sarasota, Florida, United States

University of Kentucky

Lexington, Kentucky, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Medical University of South Carolina

Orangeburg, South Carolina, United States

Spartanburg Medical System

Spartanburg, South Carolina, United States

Bluff City Vascular

Memphis, Tennessee, United States

Texas Research Institute

Fort Worth, Texas, United States

Humble Vascular Surgical Center

Humble, Texas, United States

San Antonio Kidney Disease Center

San Antonio, Texas, United States

Sentara Vascular Specialists

Virginia Beach, Virginia, United States

University Health Network

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06807099


Related Trials